[New oral antidiabetic agents].
Doi
K
K
Department of Internal Medicine, Kobe University School of Medicine.
D000818:Animals; D003511:Cyclohexanols; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D004341:Drug Evaluation; D005907:Gliclazide; D005905:Glyburide; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007093:Imidazoles; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D015394:Molecular Structure; D011759:Pyrrolidines; D013268:Stimulation, Chemical; D013453:Sulfonylurea Compounds
D003511:Cyclohexanols; D007004:Hypoglycemic Agents; D007093:Imidazoles; D007328:Insulin; D011759:Pyrrolidines; D013453:Sulfonylurea Compounds; C054577:AO 128; C021239:pirogliride; C032368:midaglizole; C057619:glimepiride; C044425:linogliride; D005907:Gliclazide; D005905:Glyburide